Expression of the HER family mRNA in breast cancer tissue and association with cell cycle inhibitors p21waf1 and p27kip1

被引:0
作者
Kalemi, Theodora G.
Papazisis, Konstantincis T.
Lambropoulos, Alexandros F. [1 ]
Voyatzi, Soultana
Kotsis, Alexandros
Kortsaris, Alexandros H.
机构
[1] Aristotle Univ Thessaloniki, Fac Med, Dept Biol & Genet, GR-54124 Thessaloniki, Greece
[2] Theagen Canc Inst, Dept Res, Thessaloniki 54007, Greece
[3] Democritus Univ Thrace, Dept Med, Biochem Lab, Alexandroupolis 68100, Greece
关键词
HER1-4; receptor tyrosine kinases; breast cancer; CDK-inhibitors; p21; p27;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The HER family of the receptor tyrosine kinases epidermal growth factor receptor (EGFR), HER2, HER3 and HER4 are involved in the pathogenesis of many human malignancies. Although there is extensive literature on the expression of single HER-2 and EGFR receptors in breast cancer, little is known concerning the simultaneous expression at the mRNA level of these four receptors in human breast tissue and their influence in downstream signaling pathways that control cell cycle and proliferation. Materials and Methods: The mRNA expression pattern of the four HER-receptors has been investigated and correlated with the expression of the cyclin-dependent kinase (CDK) inhibitors p21(Waf1) and p27(Kip1) in 67 breast cancer specimens. Results: A positive correlation between HER-3 and HER-4 mRNA levels and a negative correlation between HER2 and HER-3 was found. Compared to normal breast tissue, all four receptors were overexpressed in breast tumors and the strongest overexpression was found for HER-3 (p=0.001). HER-4 expression was inversely related to histopathological grading (HPG), suggesting that elevated HER-4 mRNA expressions could be a biological marker of a more differentiated phenotype. The expression of p21(Waf1) protein was higher in HER-2-negative tumors, compared to HER-2-positive breast carcinomas. Compared to normal breast tissue, p21 Delta, the 19 kDa degraded form of p21 protein, was markedly expressed in breast cancer (p < 0.001). Conversely, p27(Kip1) was positively associated with HER-2 receptor and inversely associated with HER-3. Conclusion: The HER family members are overexpressed in breast cancer. Complex patterns of HER family expression were observed and the effect on cell cycle regulation was dependent on that pattern.
引用
收藏
页码:913 / 920
页数:8
相关论文
共 64 条
[41]   Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells [J].
Poon, RYC ;
Hunter, T .
ONCOGENE, 1998, 16 (10) :1333-1343
[42]   IDENTIFICATION OF C-ERBB-3 BINDING-SITES FOR PHOSPHATIDYLINOSITOL 3'-KINASE AND SHC USING AN EGF RECEPTOR C-ERBB-3 CHIMERA [J].
PRIGENT, SA ;
GULLICK, WJ .
EMBO JOURNAL, 1994, 13 (12) :2831-2841
[43]  
Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO
[44]  
2-V
[45]   The ErbB/HER receptor protein-tyrosine kinases and cancer [J].
Roskoski, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 319 (01) :1-11
[46]  
Sherr CJ, 2000, CANCER RES, V60, P3689
[47]   CDK inhibitors:: positive and negative regulators of G1-phase progression [J].
Sherr, CJ ;
Roberts, JM .
GENES & DEVELOPMENT, 1999, 13 (12) :1501-1512
[48]   HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].
SLAMON, DJ ;
CLARK, GM ;
WONG, SG ;
LEVIN, WJ ;
ULLRICH, A ;
MCGUIRE, WL .
SCIENCE, 1987, 235 (4785) :177-182
[49]   Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status -: Results from International Breast Cancer Study Group Trial V [J].
Spataro, VJ ;
Litman, H ;
Viale, G ;
Maffini, F ;
Masullo, M ;
Golouh, R ;
Martinez-Tello, FJ ;
Grigolato, P ;
Shilkin, KB ;
Gusterson, BA ;
Castiglione-Gertsch, M ;
Price, K ;
Lindtner, J ;
Cortés-Funes, H ;
Simoncini, E ;
Byrne, MJ ;
Collins, J ;
Gelber, RD ;
Coates, AS ;
Goldhirsch, A .
CANCER, 2003, 97 (07) :1591-1600
[50]  
Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO